longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Anthropic selects Twist Bioscience as independent evaluator for AI-designed protein testing

TradingView
Aug 19, 2026 at 10:03 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Twist Bioscience has been selected by Anthropic as an independent evaluator to rapidly produce and test AI-designed proteins at scale. This collaboration involves data from a multi-arm protein design campaign using Claude Opus 4.8 and Mythos Preview, focusing on testing protein binding capabilities.

Twist Bioscience announced it was chosen by Anthropic to rapidly produce and test AI-designed proteins at scale.

Key Highlights:

  • Anthropic reported receiving data from a multi-arm protein design campaign using Claude Opus 4.8 and Mythos Preview.
  • Anthropic selected Twist Bioscience as an independent evaluator to produce at scale and test AI-designed proteins for binding.
  • Disclosure filed under Item 7.01; furnished information not deemed "filed" or incorporated by reference in other SEC filings.

Original SEC Filing: Twist Bioscience Corp [ TWST ] - 8-K - Aug. 18, 2026

Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Login to unlock276characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Twist Bioscience

Twist Bioscience

USTWST

+0.92%

Anthropic

Anthropic

NAANTH

LongbridgeAI